More than two in five (42%) or 57.4 million adults under 65 with private insurance could be eligible under clinical criteria for GLP-1 drugs used to treat people with type 2 diabetes, obesity, or excess weight and weight-related health issues, according to a new KFF analysis. Though only about 3% […]
Day: September 6, 2024
DB Endgame update Q3 2024
Discussing emerging issues and market activity in the DB Endgame space.
Benefit consulting excellence celebrated at WSB Awards
For the third consecutive year, we were named ‘Employee Benefits Consultant of the Year’ at the Workplace Savings and Benefits (WSB) awards.